Proactive Investors - Run By Investors For Investors

Physiomics extends lucrative relationship with Merck

Physiomics will once again supply its technology to Merck in 2019, for which it will receive around £435,000
thumbs up
The two companies have been working together for eight years now

Physiomics PLC (LON:PYC) has extended its relationship with Merck KGaA by signing another lucrative contract with the multi-billion-dollar German firm.

AIM-quoted Physiomics owns a technology that can help to predict the effect of a drug on cancer.

READ: Merck contract boosts Physiomics’ annual revenue

The two companies have entered into contracts worth £435,000 for projects that are due to be completed in 2019.

They have also provisionally agreed that they will aim to publish selected elements of their work at one or more major conferences in 2019.

“We are now entering the eighth year of our relationship with Merck, during which time we have provided a range of pre-clinical and clinical predictive modelling services using our Virtual Tumour technology,” said chief executive Jim Millen.

“We remain immensely proud to be working with one of the world's foremost pharmaceutical companies, in an area as important and rapidly growing as oncology.  We look forward to this collaboration continuing.”

Physiomics shares were flat at 4.15p in early deals on Monday.

View full PYC profile View Profile

Physiomics Plc Timeline

Related Articles

cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
researcher
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use